Open / Translational Research Studies
Stomach Cancer, Oesophageal Cancer
If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
STING and DNA damage repair markers as predictors for response to chemotherapy and immunotherapy in gastric and oesophageal cancer
Purpose of the Study
Traditional anti-cancer therapies, such as radiation and chemotherapy, cause cancer cell death by directly or indirectly causing critical damage to tumour DNA. There is a novel protein marker known as STING which detects leaked DNA fragments from the cancer cells, an indicator the cell has been damaged, and instructs the cancer cell to be destroyed. Gastro-oesophageal cancers express very low levels of STING and it is thought that this may, in part, explain why these cancers evade cell death by the immune system as well as their poor response to traditional treatment.
This translational study aims to determine what impact STING levels have on the ability for gastro-oesophageal cancers to respond to treatment, how this impacts the immune response to cancer and ultimately the ability to survive.
Please contact Dr Sarah Hayes (email@example.com) if you have questions regarding this study.
A/Professor Weng Ng
AGITG Philanthropy (Major Donor Funding)
Open / Translational Research Studies
Stomach Cancer, Oesophageal Cancer
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.
PALliative oEsOphageal cancer chemoradioimmunotherapy (PALEO): A multicentre Phase II Clinical Trial
PALEO is a single arm, multicentre Phase II trial in adults with previously untreated oligometastatic oesophageal or gastro-oesophageal (GOJ) carcinoma and symptomatic dysphagia. The trial objective is to assess the efficacy and tolerability of concurrent palliative chemoradiotherapy and anti-PD1/PDL1 immunotherapy in patients with oligometastatic oesophageal and GOJ cancer.
All participants will receive 2 weeks of therapy with concurrent hypofractionated radiotherapy (30Gy/10 fractions), weekly carboplatin AUC2, weekly paclitaxel 50mg/m2 and q2weekly anti-PD1/PDL1 immunotherapy, followed by anti-PD1/PDL1 monotherapy continuing 2 weekly for up to 12 months.
For further immune priming, stereotactic radiotherapy (24Gy/3 fractions) to a single metastasis will be delivered 4 weeks post chemoradiotherapy completion.
Primary endpoints are continued improvement in dysphagia Mellow score at 6 months and progression free survival. Secondary endpoints are maximum improvement in Mellow score, nutritional status change, QOL, endoscopic response, response rate in metastatic lesions, toxicity and overall survival.
The typical presentation of oesophageal or gastro-oesophageal (GOJ) cancer is with dysphagia (difficulty swallowing) due to the primary tumour. On subsequent staging investigations the majority of patients will be diagnosed with de novo metastatic disease, for which there is no accepted standard of care in the setting of a symptomatic primary tumour. Patients require expeditious and effective relief of their dysphagia within an overall treatment plan that is palliative in intent. Treatment options include best supportive care, chemotherapy, radiotherapy, stenting, or a combination of these.
Clinical goals in the palliative setting include return to normal function, minimally toxic therapy, durable treatment responses, patient quality of life and prolonged survival.
In a recent Phase I clinical trial we have completed in this patient group, we have shown that first line concurrent chemoradiotherapy (30Gy) with low dose weekly carboplatin and paclitaxel can be safely hypofractionated from 15 to 10 fractions, thereby reducing the treatment burden to the patient and health system.
Of the 15 patients with at least 6 weeks follow up, all have achieved improvement in their dysphagia, and the majority have returned to a normal diet. At least 3 patients have achieved complete relief of their dysphagia beyond 1 year. In the current proposal, we aim to further prolong the dysphagia relief provided by our well-tolerated 2 week CRT protocol while simultaneously providing distant disease control.
Clinical Trial Design
The Phase II PALEO clinical trial adds concurrent checkpoint inhibition with single agent anti-PD1/PDL1 monoclonal antibody therapy to chemoradiotherapy, and then continuing for up to 12 months. Stereotactic radiotherapy (SBRT) is delivered to a single metastasis post-chemoradiotherapy. Despite the high mutational burden of oesophagogastric cancer, 2 single agent immune-oncology treatment has to date provided low response rates, 3 hence the importance of steps to ‘prime’ the immune response. We combine three strategies to both maximise clinical benefit and concurrently increase tumour antigen presentation:
- Radiotherapy to the primary tumour (explained subsequently)
- Use of paclitaxel, an immunogenic chemotherapy in the presence of radiotherapy4
- 24Gy in 3 fractions of stereotactic radiotherapy to a metastasis, given the different immune milieu of metastases, the immunogenicity of this radiation dose fractionation and early promising data suggesting an increased response rate to checkpoint inhibition with this approach.5-7
We hypothesise that this treatment combination will provide durable dysphagia relief and progression free survival with a tolerable toxicity profile. The therapeutic strategy is supported by pre-clinical8 and clinical data9-11 showing that radiotherapy increases the presentation of tumour-associated antigens which prime CD8+ T cells.12 The resultant increased immunogenicity of the malignancy, both at the irradiated site and in distant metastases, may be further augmented by immune checkpoint inhibition.13 The application of anti-PD1/PDL1 immunotherapy also capitalises on the favourable side effect profile of these agents14,15, shown in multiple randomised controlled trials (RCTs) to be better tolerated than typical platinum-based chemotherapy.16,17 Our target patient cohort has oligometastatic disease and weight loss of <10% based on data from the Australian TROG 03.01 Phase III RCT in patients with advanced/metastatic oesophageal cancer, which found these characteristics prognostic.18 We have further defined the metastatic disease as non-bulky and not requiring immediate cisplatin/oxaliplatin-based systemic chemotherapy in the judgement of the treating clinician, in line with the patient cohort recruited to our Phase I study.
Click to access the table and view recruitment data on all AGITG open trials:
Key Eligibility Criteria
- Biopsy proven carcinoma of the oesophagus or gastro-oesophageal junction
- Oligometastatic disease (1-5 lesions outside radiotherapy field on FDG-PET)
- Symptomatic dysphagia (Mellow score >0)
- ECOG performance status 0-2
- Loss of weight <10%
- Bulky or organ-threatening metastatic disease requiring higher dose chemotherapy in the judgement of the treating clinician
- Tumour HER2 positivity
- Contra-indications to carboplatin, paclitaxel or immunotherapy
- Oesophageal stent in situ
- Previous systemic therapy for oesophageal or GOJ carcinoma/Previous thoracic RT
Dr Fiona Day and Professor Jarad Martin
Detailed Information Available on
More detailed information available online at the Australian New Zealand Clinical Trial Registry (ANZCTR)